Page last updated: 2024-12-10

beta-funaltrexamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

beta-funaltrexamine: RN given refers to parent cpd(E)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5311018
CHEMBL ID473136
CHEBI ID81527
SCHEMBL ID1240811
MeSH IDM0082827

Synonyms (25)

Synonym
gtpl1631
methyl (2e)-3-{[(1s,5r,13r,14r,17s)-4-(cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7,9,11(18)-trien-14-yl]carbamoyl}prop-2-enoate
naltrexone fumarate methyl ester
2-butenoic acid, 4-(((5alpha,6beta)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl)amino)-4-oxo-, methyl ester, (e)-
beta-fna
beta-funaltrexamine
PDSP2_001549
beta funaltrexamine
PDSP2_000394
NCGC00163180-01
beta-funeltrexamine
methyl 3-[4-cyclopropylmethyl-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10-trien-14-ylcarbamoyl]-(e)-2-propenoate
bdbm50247803
methyl (2e)-3-{[(1s,5r,13r,14r,17s)-4-(cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-trien-14-yl]carbamoyl}prop-2-enoate
C18127
72782-05-9
CHEMBL473136 ,
chebi:81527 ,
SCHEMBL1240811
Q27075143
DTXSID501316803
2-butenoic acid, 4-[[(5alpha,6beta)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl]amino]-4-oxo-, methyl ester, (2e)-
2-butenoic acid, 4-[[(5alpha,6beta)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl]amino]-4-oxo-, methyl ester, (e)-
9YX958J3X9
beta-naltrexamine n-(methyl fumarate)

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacodynamic endpoints evaluated were respiratory depression, measured as the change in arterial blood pCO(2), pO(2), and pH levels; and antinociception, measured by the tail-flick technique."( Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effects of main active metabolites of tramadol, (+)-O-desmethyltramadol and (-)-O-desmethyltramadol, in rats.
Calvo, R; Garrido, MJ; Pavón, JM; Trocóniz, IF; Valle, M, 2000
)
0.31
"5 Hz frequency band of the EEG as pharmacodynamic endpoint."( Pharmacokinetic-pharmacodynamic analysis of the EEG effect of alfentanil in rats following beta-funaltrexamine-induced mu-opioid receptor "knockdown" in vivo.
Cox, E; Danhof, M; Garrido, M; Gubbens-Stibbe, J; IJzerman, A; Künzel, D; Tukker, E; van der Graaf, PH; von Frijtag, J, 2000
)
0.53

Compound-Compound Interactions

ExcerptReferenceRelevance
"Effects of the kappa opioid agonists, spiradoline (U62,066), enadoline (CI-977) and U69,593, were examined alone and in combination with the opioid antagonists quadazocine and beta-funaltrexamine in squirrel monkeys that responded under a schedule of shock titration."( Antinociceptive and response rate-altering effects of kappa opioid agonists, spiradoline, enadoline and U69,593, alone and in combination with opioid antagonists in squirrel monkeys.
Dykstra, LA; Pitts, RC, 1994
)
0.48

Bioavailability

ExcerptReferenceRelevance
" Our results demonstrate that cyclization might be a promising strategy to enhance bioavailability of peptides and may serve a role in the development of novel endomorphin analogs with increased therapeutic potential."( Synthesis and biological evaluation of cyclic endomorphin-2 analogs.
Cravezic, A; do-Rego, JC; Fichna, J; Janecka, A; Perlikowska, R; Toth, G; Wyrebska, A, 2010
)
0.36

Dosage Studied

Systemic administration of beta-funaltrexamine (beta-FNA) 24 hr before analgesic testing produced approximately a 10-fold parallel shift in the dose-response curves of the prototypic mu agonists morphine, I-methadone, fentanyl and etorphine.

ExcerptRelevanceReference
" catheters, dose-response curves were carried out using the hot plate (HP) test for a number of receptor-preferring opioids."( Characteristics of dose-dependent antagonism by beta-funaltrexamine of the antinociceptive effects of intrathecal mu agonists.
Mjanger, E; Yaksh, TL, 1991
)
0.54
") of a 15 mg naltrexone pellet there was a significant shift to the right of the fentanyl dose-response curves for analgesia and lethality."( Evaluation of receptor mechanism mediating fentanyl analgesia and toxicity.
Jang, Y; Yoburn, BC, 1991
)
0.28
" In dose-response studies, beta-FNA antagonized all the actions with similar potencies (ID50 values of 12."( Comparison of naloxonazine and beta-funaltrexamine antagonism of mu 1 and mu 2 opioid actions.
Pasternak, GW; Paul, D; Pick, CG, 1991
)
0.57
" Antinociceptive dose-response curves were constructed for mu ([D-Ala2,NMePhe4,Gly-ol]enkephalin, DAGO; morphine) and delta ([D-Pen2,D-Pen5]enkephalin, DPDPE)-agonists in the absence, and in the presence of the mu non-surmountable antagonist, beta-funaltrexamine (beta-FNA) or the delta-antagonist ICI 174,864 (N,N-diallyl-Tyr-Aib-Aib-Phe-Leu-OH, where Aib is alpha-amino-isobutyric acid)."( Opioid delta-receptor involvement in supraspinal and spinal antinociception in mice.
Heyman, JS; Mosberg, HI; Mulvaney, SA; Porreca, F, 1987
)
0.45
" In the mouse vas deferens, pre-treatment with beta-FNA (1 X 10(-6)M) produced a similar shift in the dose-response curves for normorphine as in the guinea-pig ileum."( Determination of the receptor selectivity of opioid agonists in the guinea-pig ileum and mouse vas deferens by use of beta-funaltrexamine.
Hayes, AG; Sheehan, MJ; Tyers, MB, 1985
)
0.48
" The dosage of beta-FNA utilized (5 mg/kg) blocked morphine-induced analgesia (2 mg/kg morphine sulfate, SC) for each injection period (i."( beta-Funaltrexamine (beta-FNA) and the regulation of body and brain development in rats.
McLaughlin, PJ; Zagon, IS, 1986
)
1.71
"Systemic administration of beta-funaltrexamine (beta-FNA) 24 hr before analgesic testing produced approximately a 10-fold parallel shift in the dose-response curves of the prototypic mu agonists morphine, I-methadone, fentanyl and etorphine in the mouse abdominal constriction test."( Use of beta-funaltrexamine to determine mu opioid receptor involvement in the analgesic activity of various opioid ligands.
Hynes, MD; Leander, JD; Reel, JK; Zimmerman, DM, 1987
)
1.03
" Both antagonists produced large shifts in the dose-response curves to the mu-agonists, morphine and fentanyl, confirming their mu-antagonist activity."( Reversal by beta-funaltrexamine and 16-methyl cyprenorphine of the antinociceptive effects of opioid agonists in the mouse and guinea-pig.
Birch, PJ; Hayes, AG, 1988
)
0.65
") produced a dose-response curve with a reduced maximum effect."( Relative involvement of receptor subtypes in opioid-induced inhibition of intestinal motility in mice.
Takemori, AE; Ward, SJ,
)
0.13
", the morphine dose-response curve shifted to the left and the ED50 value of morphine decreased."( Effects of a highly selective nonpeptide delta opioid receptor agonist, TAN-67, on morphine-induced antinociception in mice.
Endoh, T; Misawa, M; Mori, T; Nagase, H; Suzuki, T; Tsuji, M, 1995
)
0.29
"5 micrograms), parallel rightward shifts of both morphine and RB 101 (mixed enkephalin-degrading-enzyme inhibitor) dose-response curves, were observed, but the concentration of beta-FNA required to reduce the analgesic responses was about 10 times higher for RB 101 (0."( Assessment of endogenous enkephalins efficacy in the hot plate test in mice: comparative study with morphine.
Noble, F; Roques, BP, 1995
)
0.29
"1-fold leftward shift in the dose-response curve."( Intrathecal Tyr-W-MIF-1 produces potent, naloxone-reversible analgesia modulated by alpha 2-adrenoceptors.
Gergen, KA; Kastin, AJ; Paul, D; Zadina, JE, 1996
)
0.29
" Antagonist dose-response curves were plotted."( 5-HT spinal antinociception involves mu opioid receptors: cross tolerance and antagonist studies.
Freeman, J; Gent, JP; Goodchild, CS; Guo, Z, 1997
)
0.3
" TAPA dose-response curve for antinociception."( Selective antagonism by naloxonazine of antinociception by Tyr-D-Arg-Phe-beta-Ala, a novel dermorphin analogue with high affinity at mu-opioid receptors.
Hayashi, T; Kisara, K; Kutsuwa, M; Sakurada, C; Sakurada, S; Sakurada, T; Sato, T; Takeda, S; Tan-No, K; Yuki, M, 2000
)
0.31
"8 mg/kg) produced a 74-fold increase in the ED(50) of morphine while showing no effect on bremazocine or BW373U86 dose-response curves."( Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
Broadbear, JH; Burke, TF; Husbands, SM; Lewis, JW; Sumpter, TL; Traynor, JR; Woods, JH, 2000
)
0.51
"1 times more potent during acute and chronic CO, and the E(max) values of the dose-response curves increased 35% during inflammation."( Intestinal inflammation enhances the inhibitory effects of opioids on intestinal permeability in mice.
Pol, O; Puig, MM; Valle, L, 2001
)
0.31
" Because its pharmacological characterization has not been fully identified, the present study examined whether a dose-response range of general and selective opioid antagonists as well as antisense oligodeoxynucleotide (AS ODN) opioid probes altered daytime feeding over a 4-h time course elicited by dynorphin."( Dynorphin A(1-17)-induced feeding: pharmacological characterization using selective opioid antagonists and antisense probes in rats.
Bodnar, RJ; Grossman, HC; Hadjimarkou, MM; Pasternak, GW; Rossi, GC; Silva, RM, 2002
)
0.31
" However, injection of nifedipine into the vPAG potentiated the antinociceptive effect of endomorphin-1, producing a significant leftward shift in the dose-response curve of endomorphin-1 in both the tail-flick and tail-pressure tests."( Nifedipine potentiates the antinociceptive effect of endomorphin-1 microinjected into the periaqueductal gray in rats.
Cousins, MJ; Fink, DJ; Hao, S; Iwasaki, H; Mamiya, K; Mata, M; Takahata, O, 2003
)
0.32
" MOPr agonist efficacy was evaluated by microinjecting the irreversible opioid receptor antagonist β-funaltrexamine hydrochloride (β-FNA) into the vlPAG prior to a dose-response analysis of morphine and fentanyl antinociception."( Differential development of antinociceptive tolerance to morphine and fentanyl is not linked to efficacy in the ventrolateral periaqueductal gray of the rat.
Bobeck, EN; Haseman, RA; Hong, D; Ingram, SL; Morgan, MM, 2012
)
0.38
" One way to interpret this pattern of effects is that pretreatment with naloxone appeared to produce a shift in the dose-response curve for METH."( The selective μ opioid receptor antagonist β-funaltrexamine attenuates methamphetamine-induced stereotypical biting in mice.
Fukushima, Y; Hall, FS; Kitanaka, J; Kitanaka, N; Kubo, H; Morita, Y; Nishiyama, N; Sawai, T; Takahashi, H; Takemura, M; Tanaka, K; Tatsuta, T; Uhl, GR; Watabe, K, 2013
)
0.39
" A distinct dose-response effects of these peptides on cocaine locomotion probably arise from differential functional activation (targeting) of the DOR and MOR by both deltorphins analogs."( Involvement of delta and mu opioid receptors in the acute and sensitized locomotor action of cocaine in mice.
Gibula-Bruzda, E; Izdebski, J; Kotlinska, JH; Witkowska, E, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
morphinane alkaloidAn isoquinoline alkaloid based on a morphinan skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency10.00001.000010.475628.1838AID1457
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Muscarinic acetylcholine receptor M2Rattus norvegicus (Norway rat)IC50 (µMol)0.08200.00053.314249.5000AID224721
Prostaglandin G/H synthase 1Homo sapiens (human)IC50 (µMol)0.08200.00021.557410.0000AID224721
Delta-type opioid receptorMus musculus (house mouse)IC50 (µMol)0.08200.00010.729810.0000AID148769
Kappa-type opioid receptorMus musculus (house mouse)IC50 (µMol)0.08200.00131.538010.0000AID148769
Mu-type opioid receptorHomo sapiens (human)Ki0.00040.00000.419710.0000AID347309; AID415721
Delta-type opioid receptorHomo sapiens (human)Ki0.02780.00000.59789.9300AID347310; AID415722
Kappa-type opioid receptorHomo sapiens (human)Ki0.00090.00000.362410.0000AID347311; AID415723
Mu-type opioid receptorMus musculus (house mouse)IC50 (µMol)0.08200.00081.699210.0000AID148769; AID224721
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (58)

Processvia Protein(s)Taxonomy
prostaglandin biosynthetic processProstaglandin G/H synthase 1Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 1Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 1Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 1Homo sapiens (human)
regulation of cell population proliferationProstaglandin G/H synthase 1Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMu-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
sensory perceptionMu-type opioid receptorHomo sapiens (human)
negative regulation of cell population proliferationMu-type opioid receptorHomo sapiens (human)
sensory perception of painMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
behavioral response to ethanolMu-type opioid receptorHomo sapiens (human)
positive regulation of neurogenesisMu-type opioid receptorHomo sapiens (human)
negative regulation of Wnt protein secretionMu-type opioid receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMu-type opioid receptorHomo sapiens (human)
calcium ion transmembrane transportMu-type opioid receptorHomo sapiens (human)
cellular response to morphineMu-type opioid receptorHomo sapiens (human)
regulation of cellular response to stressMu-type opioid receptorHomo sapiens (human)
regulation of NMDA receptor activityMu-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayMu-type opioid receptorHomo sapiens (human)
immune responseDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerDelta-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
adult locomotory behaviorDelta-type opioid receptorHomo sapiens (human)
negative regulation of gene expressionDelta-type opioid receptorHomo sapiens (human)
negative regulation of protein-containing complex assemblyDelta-type opioid receptorHomo sapiens (human)
positive regulation of CREB transcription factor activityDelta-type opioid receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationDelta-type opioid receptorHomo sapiens (human)
response to nicotineDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
eating behaviorDelta-type opioid receptorHomo sapiens (human)
regulation of mitochondrial membrane potentialDelta-type opioid receptorHomo sapiens (human)
regulation of calcium ion transportDelta-type opioid receptorHomo sapiens (human)
cellular response to growth factor stimulusDelta-type opioid receptorHomo sapiens (human)
cellular response to hypoxiaDelta-type opioid receptorHomo sapiens (human)
cellular response to toxic substanceDelta-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayDelta-type opioid receptorHomo sapiens (human)
immune responseKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
chemical synaptic transmissionKappa-type opioid receptorHomo sapiens (human)
sensory perceptionKappa-type opioid receptorHomo sapiens (human)
locomotory behaviorKappa-type opioid receptorHomo sapiens (human)
sensory perception of painKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
response to insulinKappa-type opioid receptorHomo sapiens (human)
positive regulation of dopamine secretionKappa-type opioid receptorHomo sapiens (human)
negative regulation of luteinizing hormone secretionKappa-type opioid receptorHomo sapiens (human)
response to nicotineKappa-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
maternal behaviorKappa-type opioid receptorHomo sapiens (human)
eating behaviorKappa-type opioid receptorHomo sapiens (human)
response to estrogenKappa-type opioid receptorHomo sapiens (human)
estrous cycleKappa-type opioid receptorHomo sapiens (human)
response to ethanolKappa-type opioid receptorHomo sapiens (human)
regulation of saliva secretionKappa-type opioid receptorHomo sapiens (human)
behavioral response to cocaineKappa-type opioid receptorHomo sapiens (human)
sensory perception of temperature stimulusKappa-type opioid receptorHomo sapiens (human)
defense response to virusKappa-type opioid receptorHomo sapiens (human)
cellular response to lipopolysaccharideKappa-type opioid receptorHomo sapiens (human)
cellular response to glucose stimulusKappa-type opioid receptorHomo sapiens (human)
positive regulation of p38MAPK cascadeKappa-type opioid receptorHomo sapiens (human)
positive regulation of potassium ion transmembrane transportKappa-type opioid receptorHomo sapiens (human)
response to acrylamideKappa-type opioid receptorHomo sapiens (human)
positive regulation of eating behaviorKappa-type opioid receptorHomo sapiens (human)
conditioned place preferenceKappa-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayKappa-type opioid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (17)

Processvia Protein(s)Taxonomy
peroxidase activityProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 1Homo sapiens (human)
protein bindingProstaglandin G/H synthase 1Homo sapiens (human)
heme bindingProstaglandin G/H synthase 1Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 1Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 1Homo sapiens (human)
G-protein alpha-subunit bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled receptor activityMu-type opioid receptorHomo sapiens (human)
beta-endorphin receptor activityMu-type opioid receptorHomo sapiens (human)
voltage-gated calcium channel activityMu-type opioid receptorHomo sapiens (human)
protein bindingMu-type opioid receptorHomo sapiens (human)
morphine receptor activityMu-type opioid receptorHomo sapiens (human)
G-protein beta-subunit bindingMu-type opioid receptorHomo sapiens (human)
neuropeptide bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityDelta-type opioid receptorHomo sapiens (human)
protein bindingDelta-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled enkephalin receptor activityDelta-type opioid receptorHomo sapiens (human)
neuropeptide bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityKappa-type opioid receptorHomo sapiens (human)
protein bindingKappa-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingKappa-type opioid receptorHomo sapiens (human)
dynorphin receptor activityKappa-type opioid receptorHomo sapiens (human)
neuropeptide bindingKappa-type opioid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (28)

Processvia Protein(s)Taxonomy
photoreceptor outer segmentProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 1Homo sapiens (human)
Golgi apparatusProstaglandin G/H synthase 1Homo sapiens (human)
intracellular membrane-bounded organelleProstaglandin G/H synthase 1Homo sapiens (human)
extracellular exosomeProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 1Homo sapiens (human)
plasma membraneKappa-type opioid receptorMus musculus (house mouse)
endosomeMu-type opioid receptorHomo sapiens (human)
endoplasmic reticulumMu-type opioid receptorHomo sapiens (human)
Golgi apparatusMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
axonMu-type opioid receptorHomo sapiens (human)
dendriteMu-type opioid receptorHomo sapiens (human)
perikaryonMu-type opioid receptorHomo sapiens (human)
synapseMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
neuron projectionMu-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneDelta-type opioid receptorHomo sapiens (human)
dendrite membraneDelta-type opioid receptorHomo sapiens (human)
presynaptic membraneDelta-type opioid receptorHomo sapiens (human)
axon terminusDelta-type opioid receptorHomo sapiens (human)
spine apparatusDelta-type opioid receptorHomo sapiens (human)
postsynaptic density membraneDelta-type opioid receptorHomo sapiens (human)
neuronal dense core vesicleDelta-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
neuron projectionDelta-type opioid receptorHomo sapiens (human)
nucleoplasmKappa-type opioid receptorHomo sapiens (human)
mitochondrionKappa-type opioid receptorHomo sapiens (human)
cytosolKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
membraneKappa-type opioid receptorHomo sapiens (human)
sarcoplasmic reticulumKappa-type opioid receptorHomo sapiens (human)
T-tubuleKappa-type opioid receptorHomo sapiens (human)
dendriteKappa-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneKappa-type opioid receptorHomo sapiens (human)
presynaptic membraneKappa-type opioid receptorHomo sapiens (human)
perikaryonKappa-type opioid receptorHomo sapiens (human)
axon terminusKappa-type opioid receptorHomo sapiens (human)
postsynaptic membraneKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
neuron projectionKappa-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorMus musculus (house mouse)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (75)

Assay IDTitleYearJournalArticle
AID79537Compound was evaluated for irreversible antagonist activity in Guinea pig ileum (GPI) agonist (morphine) IC50 after antagonist treatment (20 nM) divided by the agonist control IC501987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Nonequilibrium opioid antagonist activity of 6,14-dideoxynaltrexone derivatives.
AID415722Displacement of [3H]NTI from delta opioid receptor expressed in CHO cells2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
14-O-Heterocyclic-substituted naltrexone derivatives as non-peptide mu opioid receptor selective antagonists: design, synthesis, and biological studies.
AID232086Compound was tested for irreversible antagonist activity against opioid receptor in mouse vas deferens, expressed as IC50 of morphine divided by the compound1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Irreversible blockage of opioid receptor types by ester homologues of beta-funaltrexamine.
AID415721Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
14-O-Heterocyclic-substituted naltrexone derivatives as non-peptide mu opioid receptor selective antagonists: design, synthesis, and biological studies.
AID226807Compound was tested for irreversible antagonist activity at mu receptor by determining by ileal response to morphine after 30 min incubation at 1000 nM1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
Design and synthesis of naltrexone-derived affinity labels with nonequilibrium opioid agonist and antagonist activities. Evidence for the existence of different mu receptor subtypes in different tissues.
AID76521Irreversible antagonism to morphine was evaluated after 30 min incubation of GPI with the compound at 1000 nM conc.1983Journal of medicinal chemistry, Sep, Volume: 26, Issue:9
Importance of C-6 chirality in conferring irreversible opioid antagonism to naltrexone-derived affinity labels.
AID226796Irreversible antagonist activity at mouse vas deferens mu receptor against DADLE after 30 min at 200 nM1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
Design and synthesis of naltrexone-derived affinity labels with nonequilibrium opioid agonist and antagonist activities. Evidence for the existence of different mu receptor subtypes in different tissues.
AID20358The relative rate (to beta FNA) in the reaction of Michael acceptors with cysteine at pH 7.4 at 25 degree Celsius in the presence of 13 fold excess cysteine was reported for half-life.1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
Design and synthesis of naltrexone-derived affinity labels with nonequilibrium opioid agonist and antagonist activities. Evidence for the existence of different mu receptor subtypes in different tissues.
AID226793Compound was tested for irreversible antagonist activity at mu receptor by determining by MVD response to DADLE after 30 min incubation at 100 nM1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
Design and synthesis of naltrexone-derived affinity labels with nonequilibrium opioid agonist and antagonist activities. Evidence for the existence of different mu receptor subtypes in different tissues.
AID232077Compound was tested for irreversible antagonist activity against opioid receptor in mouse vas deferens at a concentration of 20 nM, expressed as IC50 of morphine divided by the compound1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Irreversible blockage of opioid receptor types by ester homologues of beta-funaltrexamine.
AID415720Selectivity ratio of Ki for delta opioid receptor to Ki for mu opioid receptor2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
14-O-Heterocyclic-substituted naltrexone derivatives as non-peptide mu opioid receptor selective antagonists: design, synthesis, and biological studies.
AID148897Antinociceptive activity was determined in vivo in all opioid type tests2000Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26
Synthesis and in vitro and in vivo activity of (-)-(1R,5R,9R)- and (+)-(1S,5S,9S)-N-alkenyl-, -N-alkynyl-, and -N-cyanoalkyl-5, 9-dimethyl-2'-hydroxy-6,7-benzomorphan homologues.
AID231996Ratio of effective dose of morphine at 72 hr after antagonism treatment by icv administration (4.8 nmol) divided by its control ED501993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Possible contribution of a glutathione conjugate to the long-duration action of beta-funaltrexamine.
AID225334Equivalent antagonist potencies of compound was measured after 24 hr of sc administration1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Possible contribution of a glutathione conjugate to the long-duration action of beta-funaltrexamine.
AID76590The agonist potency in the guinea pig ileal longitudinal muscle preparation (GPI) was determined relative to morphine as control1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
Design and synthesis of naltrexone-derived affinity labels with nonequilibrium opioid agonist and antagonist activities. Evidence for the existence of different mu receptor subtypes in different tissues.
AID79536Compound was evaluated for irreversible antagonist activity in Guinea pig ileum (GPI) agonist (ethylketazocine) IC50 after antagonist treatment (20 nM) divided by the agonist control IC501987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Nonequilibrium opioid antagonist activity of 6,14-dideoxynaltrexone derivatives.
AID707750Displacement of [3H]U69593 from KOR in guinea pig brain membrane2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Fumaroylamino-4,5-epoxymorphinans and related opioids with irreversible μ opioid receptor antagonist effects.
AID347309Displacement of [3H]naloxone from monocloned mu opioid receptor expressed in CHO cells2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists.
AID231983Ratio of effective dose of morphine at 24 hr after antagonism treatment by icv administration (4.8 nmol) divided by its control ED501993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Possible contribution of a glutathione conjugate to the long-duration action of beta-funaltrexamine.
AID1184631Antinociceptive activity in mouse assessed as inhibition of EM-2-induced jumping at 1 ug, icv by hot-plate test2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
Antinociceptive and antidepressant-like action of endomorphin-2 analogs with proline surrogates in position 2.
AID415719Selectivity ratio of Ki for kappa opioid receptor to Ki for mu opioid receptor2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
14-O-Heterocyclic-substituted naltrexone derivatives as non-peptide mu opioid receptor selective antagonists: design, synthesis, and biological studies.
AID226787Irreversible antagonist activity at kappa receptor as ileal response to ethylketazocine after 30 min incubation at 20 nM1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
Design and synthesis of naltrexone-derived affinity labels with nonequilibrium opioid agonist and antagonist activities. Evidence for the existence of different mu receptor subtypes in different tissues.
AID224720Inhibitory concentration against mu-opioid receptor in guinea pig ileum1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Possible contribution of a glutathione conjugate to the long-duration action of beta-funaltrexamine.
AID226633Compound was tested for irreversible antagonist activity at kappa receptor by determining by ileal response to ethylketazocine after 30 min incubation at 1000 nM1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
Design and synthesis of naltrexone-derived affinity labels with nonequilibrium opioid agonist and antagonist activities. Evidence for the existence of different mu receptor subtypes in different tissues.
AID226804Compound was tested for irreversible antagonist activity at mu receptor by determining by MVD response to morphine after 30 min incubation at 200 nM1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
Design and synthesis of naltrexone-derived affinity labels with nonequilibrium opioid agonist and antagonist activities. Evidence for the existence of different mu receptor subtypes in different tissues.
AID224721Inhibitory concentration against mu-opioid receptor in mouse vas deferens1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Possible contribution of a glutathione conjugate to the long-duration action of beta-funaltrexamine.
AID132867Antagonist potency relative to DADLE at 100 nM concentration1983Journal of medicinal chemistry, Sep, Volume: 26, Issue:9
Importance of C-6 chirality in conferring irreversible opioid antagonism to naltrexone-derived affinity labels.
AID76401Agonistic potency on the guinea pig ileal longitudinal muscle (GPI) relative to morphine.1983Journal of medicinal chemistry, Sep, Volume: 26, Issue:9
Importance of C-6 chirality in conferring irreversible opioid antagonism to naltrexone-derived affinity labels.
AID140803Compound was evaluated for irreversible antagonist activity in Mouse vas deference(MVD) agonist (morphine) IC50 after antagonist treatment (50 nM) divided by the agonist control IC501987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Nonequilibrium opioid antagonist activity of 6,14-dideoxynaltrexone derivatives.
AID1461556Antimicrobial activity against Trichomonas vaginalis after 48 hrs by neutral red staining based invert microscopic analysis2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
Antitrichomonal activity of δ opioid receptor antagonists, 7-benzylidenenaltrexone derivatives.
AID230207Inhibitory concentration of ethylketazocine determined after treating with conjugate for 60 min of guinea pig ileum then divided by control IC50 in same preparation1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Possible contribution of a glutathione conjugate to the long-duration action of beta-funaltrexamine.
AID1536327Antinociceptive activity in Kunming mouse model of thermal-induced nociception assessed as increase in latency to tail withdrawal at 10 nmol, icv measured up to 60 mins by tail flick test
AID347310Displacement of [3H]NTI from monocloned delta opioid receptor expressed in CHO cells2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists.
AID148769Compound was tested for agonist activity against opioid receptor in mouse vas deferens preparation1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Irreversible blockage of opioid receptor types by ester homologues of beta-funaltrexamine.
AID140804Compound was evaluated for agonist activity in Mouse vas deferens (MVD)1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Nonequilibrium opioid antagonist activity of 6,14-dideoxynaltrexone derivatives.
AID76517Irreversible antagonism to ethylketazocine (EK) was evaluated after 30 min incubation of GPI with the compound at 1000 nM conc.1983Journal of medicinal chemistry, Sep, Volume: 26, Issue:9
Importance of C-6 chirality in conferring irreversible opioid antagonism to naltrexone-derived affinity labels.
AID149042The compound was tested for binding affinity against opioid receptor in rat brain membranes, using [3H]dihydromorphine as the radioligand1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Irreversible blockage of opioid receptor types by ester homologues of beta-funaltrexamine.
AID132870Antagonist potency relative to morphine at 100 nM concentration1983Journal of medicinal chemistry, Sep, Volume: 26, Issue:9
Importance of C-6 chirality in conferring irreversible opioid antagonism to naltrexone-derived affinity labels.
AID232078Compound was tested for irreversible antagonist activity against opioid receptor in mouse vas deferens at a concentration of 20 nM, expressed as IC50 of nalorphine divided by the compound1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Irreversible blockage of opioid receptor types by ester homologues of beta-funaltrexamine.
AID111822The agonist potency was assessed by measuring the inhibition of contraction at a single concentration (200 nM).1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
Design and synthesis of naltrexone-derived affinity labels with nonequilibrium opioid agonist and antagonist activities. Evidence for the existence of different mu receptor subtypes in different tissues.
AID347311Displacement of [3H]norBNI from monocloned kappa opioid receptor expressed in CHO cells2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists.
AID76379Tested for potent reversible agonist activity on electrically stimulated guinea pig ileal longitudinal muscle preparation1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
A novel opioid receptor site directed alkylating agent with irreversible narcotic antagonistic and reversible agonistic activities.
AID231989Ratio of effective dose of morphine at 2 hr after antagonist treatment by icv administration (4.8 nmol) divided by its control1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Possible contribution of a glutathione conjugate to the long-duration action of beta-funaltrexamine.
AID347312Selectivity ratio of Ki for monocloned delta opioid receptor to Ki for monocloned mu opioid receptor2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists.
AID230209Inhibitory concentration of morphine determined after treating with conjugate for 60 min of guinea pig ileum then divided by control IC50 in same preparation1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Possible contribution of a glutathione conjugate to the long-duration action of beta-funaltrexamine.
AID707752Displacement of [3H]DAMGO from MOR in guinea pig brain membrane2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Fumaroylamino-4,5-epoxymorphinans and related opioids with irreversible μ opioid receptor antagonist effects.
AID230208Inhibitory concentration of ethylketazocine determined after treating with conjugate for 60 min of mouse vas deferens then divided by control IC50 in same preparation1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Possible contribution of a glutathione conjugate to the long-duration action of beta-funaltrexamine.
AID225333Equivalent antagonist potencies of compound was measured after 24 hr of icv administration1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Possible contribution of a glutathione conjugate to the long-duration action of beta-funaltrexamine.
AID76519Irreversible antagonism to ethylketazocine (EK) was evaluated after 30 min incubation of GPI with the compound at 20 nM conc.1983Journal of medicinal chemistry, Sep, Volume: 26, Issue:9
Importance of C-6 chirality in conferring irreversible opioid antagonism to naltrexone-derived affinity labels.
AID132334Agonist activity measured on mouse vas deferens (MVD)1983Journal of medicinal chemistry, Sep, Volume: 26, Issue:9
Importance of C-6 chirality in conferring irreversible opioid antagonism to naltrexone-derived affinity labels.
AID226803Compound was tested for irreversible antagonist activity at mu receptor by determining by MVD response to morphine after 30 min incubation at 100 nM1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
Design and synthesis of naltrexone-derived affinity labels with nonequilibrium opioid agonist and antagonist activities. Evidence for the existence of different mu receptor subtypes in different tissues.
AID707751Displacement of [3H]Cl-DPDPE from DOR in guinea pig brain membrane2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Fumaroylamino-4,5-epoxymorphinans and related opioids with irreversible μ opioid receptor antagonist effects.
AID415724Antagonist activity against mu opioid receptor expressed in CHO cells assessed as stimulation [35S]GTPgammaS binding relative to DAMGO2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
14-O-Heterocyclic-substituted naltrexone derivatives as non-peptide mu opioid receptor selective antagonists: design, synthesis, and biological studies.
AID226740Compound was tested for agonist potency against opioid receptor in guinea pig ileal longitudinal muscle expressed as IC50 of morphine divided by the compound1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Irreversible blockage of opioid receptor types by ester homologues of beta-funaltrexamine.
AID132869Antagonist potency relative to DADLE at 200 nM concentration1983Journal of medicinal chemistry, Sep, Volume: 26, Issue:9
Importance of C-6 chirality in conferring irreversible opioid antagonism to naltrexone-derived affinity labels.
AID19551The half-life period in the reaction of Michael acceptors with cysteine at pH 7.41984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
Design and synthesis of naltrexone-derived affinity labels with nonequilibrium opioid agonist and antagonist activities. Evidence for the existence of different mu receptor subtypes in different tissues.
AID415723Displacement of [3H]norBNI from kappa opioid receptor expressed in CHO cells2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
14-O-Heterocyclic-substituted naltrexone derivatives as non-peptide mu opioid receptor selective antagonists: design, synthesis, and biological studies.
AID232594Ratio of Equivalent antagonist potencies after 24 hr of icv administration/Equivalent antagonist potencies after 24 hr of sc administration was determined1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Possible contribution of a glutathione conjugate to the long-duration action of beta-funaltrexamine.
AID232085Compound was tested for irreversible antagonist activity against opioid receptor in mouse vas deferens, expressed as IC50 of DADLE divided by compound1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Irreversible blockage of opioid receptor types by ester homologues of beta-funaltrexamine.
AID132872Antagonist potency relative to morphine at 200 nM concentration1983Journal of medicinal chemistry, Sep, Volume: 26, Issue:9
Importance of C-6 chirality in conferring irreversible opioid antagonism to naltrexone-derived affinity labels.
AID76523Irreversible antagonism to morphine was evaluated after 30 min incubation of GPI with the compound at 20 nM conc.1983Journal of medicinal chemistry, Sep, Volume: 26, Issue:9
Importance of C-6 chirality in conferring irreversible opioid antagonism to naltrexone-derived affinity labels.
AID79541Compound was evaluated for agonist activity in Guinea pig ileum (GPI)1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Nonequilibrium opioid antagonist activity of 6,14-dideoxynaltrexone derivatives.
AID440047Displacement of beta-[3H]FNA from mu opioid receptor in guinea pig brain membrane2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Discovery of dermorphin-based affinity labels with subnanomolar affinity for mu opioid receptors.
AID231992Ratio of effective dose of morphine at 30 min after antagonism treatment by sc administration divided by its control1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Possible contribution of a glutathione conjugate to the long-duration action of beta-funaltrexamine.
AID347313Selectivity ratio of Ki for monocloned kappa opioid receptor to Ki for monocloned mu opioid receptor2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists.
AID76518Irreversible antagonism to ethylketazocine (EK) was evaluated after 30 min incubation of GPI with the compound at 200 nM conc.1983Journal of medicinal chemistry, Sep, Volume: 26, Issue:9
Importance of C-6 chirality in conferring irreversible opioid antagonism to naltrexone-derived affinity labels.
AID230210Inhibitory concentration of morphine determined after treating with conjugate for 60 min of mouse vas deferens then divided by control IC50 in same preparation1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Possible contribution of a glutathione conjugate to the long-duration action of beta-funaltrexamine.
AID140802Compound was evaluated for irreversible antagonist activity in Mouse vas deference(MVD) agonist (DADLE) IC50 after antagonist treatment (50 nM) divided by the agonist control IC501987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Nonequilibrium opioid antagonist activity of 6,14-dideoxynaltrexone derivatives.
AID232072Compound was tested for irreversible antagonist activity against opioid receptor in mouse vas deferens at a concentration of 100 nM, expressed as IC50 of morphine divided by the compound1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Irreversible blockage of opioid receptor types by ester homologues of beta-funaltrexamine.
AID231986Ratio of effective dose of morphine at 24 hr after antagonism treatment by sc administration divided by its control1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Possible contribution of a glutathione conjugate to the long-duration action of beta-funaltrexamine.
AID226810Irreversible antagonist activity at mu receptor by determining by ileal response to morphine after 30 min incubation at 20 nM1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
Design and synthesis of naltrexone-derived affinity labels with nonequilibrium opioid agonist and antagonist activities. Evidence for the existence of different mu receptor subtypes in different tissues.
AID1346364Human mu receptor (Opioid receptors)1998NIDA research monograph, Mar, Volume: 178Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.
AID1346329Human kappa receptor (Opioid receptors)1998NIDA research monograph, Mar, Volume: 178Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.
AID1346361Human delta receptor (Opioid receptors)1998NIDA research monograph, Mar, Volume: 178Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.
AID1346330Mouse mu receptor (Opioid receptors)1994Molecular pharmacology, Feb, Volume: 45, Issue:2
Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (526)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990103 (19.58)18.7374
1990's217 (41.25)18.2507
2000's142 (27.00)29.6817
2010's59 (11.22)24.3611
2020's5 (0.95)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.52 (24.57)
Research Supply Index6.30 (2.92)
Research Growth Index4.52 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.18%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other541 (99.82%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]